Next Article in Journal
Physical Activity and the Development of Post-Transplant Diabetes Mellitus, and Cardiovascular- and All-Cause Mortality in Renal Transplant Recipients
Next Article in Special Issue
MRI Study of Paraspinal Muscles in Patients with Amyotrophic Lateral Sclerosis (ALS)
Previous Article in Journal
Cardiovascular Events after Community-Acquired Pneumonia: A Global Perspective with Systematic Review and Meta-Analysis of Observational Studies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 9
Issue 2
10.3390/jcm9020412
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Sorting Rare ALS Genetic Variants by Targeted Re-Sequencing Panel in Italian Patients: OPTN, VCP, and SQSTM1 Variants Account for 3% of Rare Genetic Forms

by
Viviana Pensato
1,2,†,
Stefania Magri
1,†,
Eleonora Dalla Bella
2,
Pierpaola Tannorella
1,
Enrica Bersano
2,
Gianni Sorarù
3,
Marta Gatti
1,
Nicola Ticozzi
4,5,
Franco Taroni
1,
Giuseppe Lauria
2,6,
Caterina Mariotti
1,* and
Cinzia Gellera
1
1
Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy
2
3rd Neurology Unit, Motor Neuron Diseases Centre, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy
3
Department of Neuroscience, University of Padova, 35122 Padova, Italy
4
Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, 20149 Milan, Italy
5
Department of Pathophysiology and Transplantation, ‘Dino Ferrari’ Center, Università degli Studi di Milano, 20122 Milan, Italy
6
Department of Biomedical and Clinical Sciences “Luigi Sacco”, University of Milan, 20157 Milan, Italy
*
Author to whom correspondence should be addressed.
†
These authors equally contributed to this study.
J. Clin. Med. 2020, 9(2), 412; https://doi.org/10.3390/jcm9020412
Submission received: 23 December 2019 / Revised: 25 January 2020 / Accepted: 29 January 2020 / Published: 3 February 2020
(This article belongs to the Special Issue Clinical and Translational Research on Amyotrophic Lateral Sclerosis (ALS))
Browse Figure
Versions Notes

Abstract

:
Amyotrophic lateral sclerosis (ALS) is an adult-onset progressive neurodegenerative disease due to motor neuron loss variably associated with frontotemporal dementia (FTD). Next generation sequencing technology revealed an increasing number of rare and novel genetic variants and interpretation of their pathogenicity represents a major challange in the diagnosis of ALS. We selected 213 consecutive patients with sporadic or familial (16%) ALS, tested negative for SOD1, FUS, TARDBP, and C9orf72 mutations. To reveal rare forms of genetic ALS, we performed a comprehensive multi-gene panel screening including 46 genes associated with ALS, hereditary motor neuronopathies, spastic paraplegia, and FTD. Our study allowed the identification of pathogenic or likely pathogenic variants in 4.2% of patients. The genes with the highest percentage of pathogenic variants were OPTN (1%), VCP (1%) SQSTM1(1%), SETX (0.4%), FIG4 (0.4%), and GARS1 (0.4%) genes. We also found 49 novel or rare gene variants of unknown significance in 30 patients (14%), 44 unlikely pathogenic variants (39%), and 48 variants in ALS susceptibility genes. The results of our study suggest the screening of OPTN, VCP, and SQSTM1 genes in routine diagnostic investigations for both sporadic and familial cases, and confirm the importance of diagnosis and couselling for patients and their relative family members.

1. Introduction

Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative multisystem disorder characterized by loss of spinal, bulbar, and cortical motoneurons, leading to progressive and generalized paralysis. Death occurs within 3 to 5 years of onset, generally from respiratory complications [1]. The disease course may be variable and clinical presentation may include cognitive dysfunctions and behavioral changes resulting in the diagnosis of frontotemporal dementia [2]. ALS is an orphan disease with an incidence of 1–2 individuals per 100,000 each year in most countries, and a prevalence of about 5 cases per 100,000. The majority of the patients are sporadic (SALS), but in 10–20% of cases, the disease has a familial recurrence (FALS) implying a causative inheritable defect [3]. The absence of a suggestive family history, however, does not exclude a genetic cause for ALS, especially in small sized families and considering incomplete penetrance. The percentage of SALS caused by genetic variants ranges from 11% to 28% in populations of European ancestry [4,5].
Historically, the genetic studies in ALS began with the identification of missense mutations in SOD1 (superoxide dismutase 1) gene in several families displaying an autosomal dominant transmission of the disease [6]. Clinical-genetic investigations demonstrated that SOD1 is responsible for 20% of FALS and 3% of SALS, supporting the hypotesis of genetic heterogeneity in the disease.
Over the last decade, the availability of next-generation high-throughput sequencing (NGS) revealed an increasing number of new ALS-associated genes, including causative genes, genetic modulating factors for symptom severity and/or progression, and susceptibility variants possibly increasing the risk of developing the disease [7,8].
The most frequent genetic cause of ALS was found to be a large hexanucleotide repeat expansion in an intronic region of the C9orf72 gene [9,10]. This molecular defect accounts for approximately 40% of FALS cases and 5–10% of SALS. Other frequent ALS causative genes are FUS (5% FALS and < 1% SALS), and TARDBP (3% FALS and 2% SALS) [7,11,12,13,14,15]. In a percentage of ALS patients, more than one potentially pathogenic variant can be identified, suggesting an oligogenic basis of the disease with a dose-dependent gene-burden effect [16]. Recent studies proposed a multistep pathogenic model with subsequent intervening etiological events including genetic and environmental factors [17]. This model also implies that the number of steps necessary to start the neurodegenerative process in genetically mediated ALS may be reduced compared to cases without mutation, and the number of steps being variable according to the mutated gene [17,18]. Several ALS genes show pleiotropy and are associated with different clinical entities ranging from non-neurological diseases, such as glaucoma and bone diseases to ALS mimicking phenotypes such as motor neuropathies, spinal muscular atrophy, and distal myopathies [19]. Thus, it could be important to clarify whether other motor neuron disease genes may influence the pathology of genetic ALS [20]. In the view of the abundant and various genetic involvements in ALS, it is remarkable that a considerable percentage of individuals with positive family history remains without the identification of a genetic defect, suggesting a wider heterogeneity in the spectrum of the disease.
In this study we propose an NGS genetic approach to search for rare ALS gene variants in patients in which genetic defects in SOD1, FUS, TARDBP, and C9orf72 have been excluded. The aim is to reveal causative genetic factors related to ALS in a representative cohort of Italian patients, to contribute in the characterization of overlapping clinical phenotypes and improve accuracy in diagnosis and genetic counseling for this rare group of diseases.

2. Methods

2.1. Patients

Patients participating in this study were 213 unrelated ALS Italian subjects (126 men, 59%). This comprised a retrospective consecutive series of patients in which SOD1, FUS, and TARDBP gene mutations and the hexanucelotide repeat expansions in C9orf72 were previously excluded. Mean age at genetic screening was of 59 ± 13 years. Thirty-four index subjects (16%) reported a positive family history for motor neuron disease. The Ethics Standard Committee of our institution approved the study, and written informed consent was obtained from all participants.

2.2. Genetic Screening

Genomic DNA was extracted from venous peripheral blood lymphocytes by standard procedures. Preliminary mutational screening for SOD1, FUS, TARDBP, and C9orf72 genes variants was performed as previously described [10,13,14]. Next-generation sequencing was performed by either one of the following custom gene panels: a) amplicon-based customized NGS panel (Illumina TrueSeq Custom Amplicon, TSCA) covering 48 ALS/FTD genes (143 index cases); b) probe-based customized panel (Illumina Nextera Rapid Capture Custom kit, Illumina) covering 78 genes, including ALS/FTD causative and susceptibility genes, hereditary motor neuronopathy (HMN), and hereditary spastic paraplegia (HSP) genes (71 index cases). For the purposes of the study, the same set of 46 genes common for the two NGS panels were analyzed: ALS2, ANG, APEX1, ASAH1, ATXN2, BSCL2, CHCHD10, CHMP2B, CRYM, CYP27A1, DAO, DCTN1, DPP6, ELP3, EPHA4, ERBB4, FIG4, FUS, GARS1, GRN, HNRNPA1, HNRNPA2B1, HNRNPA3, IGHMBP2, MAPT, MATR3, NEFH, NEK1, OPTN, PFN1, PNPLA6, REEP1, SETX, SIGMAR1, SOD1, SPAST, SPG11, SQSTM1, TAF15, TARDBP, TREM2, TRPV4, TUBA4A, UBQLN2, VAPB, VCP (Table 1). The prescreened SOD1, FUS, TARDBP genes were also included in the gene sequencing panel, as internal control. Reference sequences for transcript (NM) and protein (NP) are reported in Supplementary Table S1.

2.3. Targeted Next-Generation Sequencing and Bioinformatic Analysis

Sequencing of enriched libraries was performed using an Illumina MiSeq sequencing device with paired end approach. Data analysis was performed using: a) MiSeq Reporter software (Illumina), for quality control, alignment against hg19 reference genome and variant calling; b) VariantStudio software (Illumina), public variation databases (Single Nucleotide Polymorphism database 137 (https://www.ncbi.nlm.nih.gov/projects/SNP), NHLBI Exome Sequencing Project 6500 (http://evs.gs.washington.edu/EVS), 1000 Genomes project (http://www.internationalgenome.org/1000-genomes-browsers/), Exome Aggregation Consortium (Exome Aggregation Consortium) and Human Gene Mutation Pro Database (http://www.hgmd.cf.ac.uk/ac/index.php) and an in-house database, for variants annotation; c) CLC Genomics Workbench software (CLCbio, Qiagen), for quality control and coverage analysis.
Variants were filtered with the following criteria: (i) variants in the coding region or in the flanking 20 bp that were (ii) absent or rare with minor allele frequency (MAF) < 1% in the population databases (dbSNP137, NHLBI E SP6500, 1000 Genomes project, and ExAC).
Taking into account the very low prevalence of ALS disease, the genetic variants with frequency > 1% in dbSNP or in Exome Variant Server or ExAC were classified as Class-1, and were escluded from subsequent analyses. In silico prediction of synonymous or intronic variants effect on splice site was performed using at least three splice prediction tools: NNSplice predictor; http://www.fruitfly.org/seq_tools/splice.html; http://wangcomputing.com/assp/. Best candidate variants were verified using Sanger methods. In subject heterozygous for a single likely pathogenic gene variant in recessive genes, we screened exon and intron-exon boundary sequences and gene copy number to search for a possible second mutation.
The genetic variants passing the filtering process were classified as “pathogenic” (Class-5), “likely pathogenic”(Class-4), “variants of unknown significance” (VUS, Class-3), and “unlikely pathogenic variants” (Class-2), according to criteria derived from a modified version of the classification proposed by Antoniadi et al. [21] (Supplementary Table S2).

3. Results

We identified a total of 160 variants in 117 out of 213 index cases (55%).
Ninenteen variants (17%) were classified as pathogenic (n = 11) or likely pathogenic (n = 8). Ten of these latter variants (Class 4–5) were in autosomal dominant ALS genes: OPTN (2), VCP (2); SQSTM1 (2) SETX (1), GARS1 (1), FIG4 (2). The remaining nine were heterozygous variants identified in autosomal recessive genes: ALS2 (1), SIGMAR1 (1), ASAH1 (1), IGHMBP2 (5), PNPLA6 (1). These patients screened negative for a second mutation in exon and intron-exon boundary sequences or gene copy number variants.
We also identified forty-nine VUS (44%, Class-3), and 44 unlikely pathogenic variants (39%, Class-2). No gene variants were detected in APEX1, BSCL2, CHCHD10, HNRNPA1, HNRNPA2B1, PFN1, REEP1, TAF15, and TUBA4 genes, and, in the prescreened FUS, SOD1, TARDBP genes (Table 2).
Forty-eight variants were found in ALS susceptibility genes (Table 3). Six variants were recurrent: the c.1472A>G in ATXN2 (2 patients), the synonimous ATXN2 variant c.3000A>G (7 patients), the c.47A>C in CRYM gene (2 patients), the c.3529 + 5G>A in DCTN1 (3 patients), the c.196-7T>G in HNRNPA3 (3 patients), and the c.1054C>A NEFH gene variant (4 patients) (Supplementary Table S3).
After classification of all gene variants, the patients were stratified according to the carried variant with the highest pathogeneicity class in ALS/FTD/HMN-HSP genes.
Nine patients carried pathogenetic or likely patogenetic variants in ALS/HMN genes (4.2%), 18 subjects carried heterozygous Class-3 variant in autosomal dominant or X-linked ALS genes (8.4%), and 12 patients (5.6%) had heterozygous variants in FTD/HMN-HSP genes. Eleven patients showed the coexistence of multiple variants of Class ≤ 3. Only one Class-3 variant (GARS1 c.303G>A; p.Arg101His) was recurrent in two patients.
Fourty-two patients (20%) carried only variants in ALS susceptibility genes (Supplementary Table S3); 18 subjects (8.4%) carried heterozygous variant in autosomal recessive ALS genes (Supplementary Table S4), and others 18 patients (8.4%) had only Class-2 variants (Supplementary Table S5). None of the index patient had more than one pathogenic or likely pathogenic variants in autosomal dominant ALS genes. No recurrent Class 4-5 variants were identified in our series (Figure 1).

Clinical Phenotypes of Patients with Class-3 to Class-5 Gene Variants

For 9 patients carrying Class-4 and Class-5 gene variants, the molecular findings supported a probable diagnosis of genetic ALS: two were subjects carrying different heterozygous Class-5 missense variants in OPTN, two subjects had different pathogenic Class-5 variants in VCP gene, one patient was compound heterozygous for a Class-4 and a Class-5 FIG4 variant (P100), two subjects carried a Class-4 missense variant and a splicing variant in SQSTM1 (P002, and P103), and one subject carried a Class-4 heterozygous GARS1 gene variant (c.1955G>A; p.Gly652Glu, P073) (Table 4). Thirty patients carried variants of unknown significance (Class-3) in ALS/HMN/FTD genes. For these patients, a definite genetic cause for the disease could not be ascertained (Table 5).

OPTN Gene

A 60 year old patient (P087) was positive for the previously described p.Gln314Leu missense heterozygous variant (Class-5) in the OPTN gene [22]. The patient presented, at age 59, progressive bulbar deficit with functional impairment of swallowing and speech. Neuropsychological evaluation showed mild depression and emotional liability. EMG showed active denervation in the bulbar district and hand muscles. The OPTN gene variant p.Gln314Leu has been described so far in two patients with motor neuron disease [22,23], and in 1/400 control subjects aged >56 years. In our “in house” database, we only observed this genetic variant in one unrelated ALS subject and in none of the 280 controls [22]. Another patient (P015) carried the previously described p.Ala481Val OPTN Class-5 missense variant. The patient was a 61-year old man presenting muscle cramps, fasciculation, increased creatine kinase (CK), progressive muscle weakness, and diffuse hyperreflexia. His mother had the diagnosis of Parkinson disease. This variant was previoulsy described in an heterozygous patient with ALS [24] and in an FTD patient who was a compound heterozygote for the p.Gln235* nonsense and the p.Ala481Val mutation [25]. A third patient carried a novel Class-3 OPTN variant, p.Leu304Phe, predicted to be deleterious at SIFT (Sorting Intolerant From Tolerant)and PolyPhen-2 prediction programs. The patient (P075) presented spasticity and muscle weakness and wasting at the age of 72, and was dignosed as having ALS at age 75. EMG showed diffuse signs of active denervation. The mother was referred to be affected by Alzheimer disease.

VCP Gene

Two patients carried previously described Class-5 heterozygous VCP variants: the p.Arg93Cys [26,27] and the p.Arg155Cys [28,29]. The patient carrying the p.Arg93Cys VCP variant (P072), presented gait difficulties at age of 47. The disease had a progressive course and at age 60 he was not able to walk independelty, had severe muscle wasting in four limbs. No bubar signs or cognitive decline were reported, but the mother and two maternal uncles were diagnosed with Alzheimer disease. A brother had the diagnosis of ALS and Paget disease.The patient carrying the p.Arg155Cys VCP gene variant (P008) had an early onset of the disease at 42 years. He presented severe and diffuse muscle weakness, muscle wasting, and fasciculations. CK level was 255 U/L (n.v. 24–195). EMG showed chronic neurogenic changes and active denervation. The mother and a maternal aunt were reported to have mild muscle weakness at lower limbs, but no specific diagnosis was made. The patient had no bone alterations or cognitive impairement. Neuropsychological tests reveal only mild deficit of episodic memory. Brain MRI was normal and the muscle biopsy showed a few fibers with rimmed vacuoles and cores. Two other patients carried Class-3 VCP variants: a 69 year old woman (P112), heterozygous for the missense p.Lys60Arg VCP variant, presented slowly progressive bulbar and limb muscle weakness and spasticity associated with cognitive decline. The second patient (P025), a 76 year old man heterozygous for the c.1696-3C>T VCP splicing variant, presented diffuse muscle weakness and wasting, cognitive and behavioral difficulties. He died one year later from disease complications.

SQSTM1 Gene

Two subjects aged 43 and 74, (P002, and P103) carried likely pathogenic variants (Class-4) in SQSTM1 gene. Both patients, aged 43 and 74, were sporadic cases and presented with clinical features consistent with the diagnosis of possible ALS (Table 4). A third patient carried a Class-3 SQSTM1 gene variant. Her presenting phenotype was characterized by diffuse and severe muscle weakness, but subsequent clinical evaluations excluded ALS disease and suggested a possible diagnosis of acquired myopathy.

FIG4 Gene

In a 27-year-old female patient (P100), genetic screening revealed a compound heterozygosity for two FIG4 missense variants: c.122T>C (p.Ile41Thr) and c.1667C>T (p.Thr556Ile). She had a clinical diagnosis of juvenile ALS with predominant upper motor neuron involvement. Clinical and molecular data of this patient was already reported by Bertolin et al. [30]. The c.122T>C pathogenic variant (Class-5) was previously reported in compound heterozygosis in a patient affected by Charcot–Marie–Tooth disease type 4J [31,32]. The c.1667C>T is a novel variant that causes the substitution of a highly conserved amino acid and was classified as Class-4. In silico studies predicted a damaging effect on protein function. FIG4 variants of Class-3 were detected in two patients. Both patients were sporadic and had different phenotypes: one subject, aged 64, presented progressive muscular wasting and peripheral neuropathy (P105), and the second case was a 39 year old woman with spastic quadriplegia since the age of 29 (P106).

SETX Gene

In patient P022, we identified a SETX Class-4 variant (c.2750T>C; p.Met917Thr) that was previously reported in an ALS patient [5]. Our patient was a 71-year-old woman presenting a bulbar onset of the disease and a severe and progressive muscular weakness and wasting. Six additional patients carried Class-3 SETX variants (Table 5). All patients were sporadic and 5 out of 6 had a classical ALS phenotype with ages at onset ranging from 43 to 79 years. One patient (P071) had a juvenile onset of slowly progressive lower motor neuron involvement.

GARS1 Gene

A rare missense likely pathogenic variant was identified in the GARS1 gene (c.1955G>A; p.Gly652Glu) predicted to be deleterious (PolyPhen-2: probably_damaging; SIFT: deleterious). Patient P073 was first evaluated at 58 years because of right foot drop without pain or sensory abnormalities. EMG showed active denervation in right tibialis anterior and extensor digitorum, with normal distal conduction velocities. Lumbar MRI showed foraminal stenosis at L3-L4, L4-L5, and L5-S1. At last evaluation, four years after symptom onset, electrophysiological studies showed severe motor axonopathy at lower limbs with active and chronic denervation signs. Motor evoked potentials disclosed reduction of the amplitude with normal latencies at four limbs, while sensory evoked potentials were normal. Based on neurophysiological data and signs of upper motor neuron involvement, a diagnosis of ALS pseudopolyneuritic type was made. Four additional patients carried GARS1 heterozygous missense variants classified as VUS. These subjects showed involvement of both upper and lower motor neurons, and one patient had bulbar onset ALS associated with FTD.

4. Discussion and Conclusion

Our knowledge about the genetic of ALS has significantly improved over the last years and the presence of causative genetic variants has been extensively investigated in different populations. The most frequently recognized disease causing mutations are found in C9orf72, SOD1, TARDBP, and FUS genes. In the patients referred to our center, including more than 400 ALS subjects, the repeat expansion in the C9orf72 gene is detected in 7.3% of cases, SOD1 gene variants in 4%, TARDBP in 1%, and FUS gene variants in 0.2% of cases. Similar percentages of causative variants in these major ALS genes were reported in other series of ALS patients [33]. In the present study, we selected 213 consecutive ALS patients negative for mutations in SOD1, FUS, TARDBP, and C9orf72, and we performed an extensive targeted NGS screening to diagnose rare forms of genetic ALS. The ALS/FTD associated genes that have been examined represent an almost complete analysis of the current list, excluding TBK1. A major difficulty in NGS analyses was the interpretation of the pathogenicity of the novel variants. Our variant classification was based on a modified version of the criteria proposed by Antoniadi et al. [21] for the diagnosis of inherited peripheral neuropathies with more restrictive criteria for the frequency of the reported variants.
Our classification consideres most of the criteria recommeded in the guidelines for the interpretation of sequence variants privided by the American College of Medical Genetics and Genomics (ACMG) [34], including population databases, in silico prediction tools, in-house variant database, and the appropriate scientific literature. However, due to predominance of late onset sporadic ALS cases in our cohort, we could not reliably count on the criteria based of segregation analysis and functional studies.
Our study allowed the identification of pathogenic or likely pathogenic variants in 4.2% of patients. This result is consistent with that reported in other high-throughput sequencing studies in which the contribution of the major ALS genes was excluded.
In fact, despite the large number of ALS screened genes and the vast number of identified variants, the diagnosis of rare genetic forms of ALS usually ranges from 4% to 5% of cases [35,36,37,38]. In recent studies on ALS patients from different populations, rare gene variants were reported in SETX (0.3–2%), ANG (0–1%), OPT (0.2–1%), ALS2 (0.3–1.5%), VCP (0.2–0.3%), UBQLN2 (0–0.7%), CHCHD10 (0.7%), VAPB (0–0.3%), and NEFH (0–0.3%) [35,36,37,38].
In our survey, the genes with the highest percentage of pathogenic variants were OPTN, VCP, and SQSTM1.
Mutations in OPTN were firstly reported to be causative of a primary open-angle glaucoma (MIM:137760), and subsequently Maruyama et al. [39] described different types of mutations (both homozygous and heterozygous) in ALS. We identified two OPTN Class-5 variants (1%), the p.Gln314Leu [22,23] and the p.Ala481Val [24,25]. The first OPTN gene variant was previously detected in two unrelated ALS patients, and in 1 out of 400 control subjects. The occurrence of the variant in a patient from our series seems to confirm its pathogenic role, although variable penetrance could also been considered [23]. The second p.Ala481Val OPTN variant was previously described in an heterozygous ALS patient from a Canadian cohort [24], and in a 64-year-old patient with FTD from a different study [25]. This latter subject was a compound heterozygote for two OPTN variants including the missense p.Ala481Val and the p.Gln235* nonsense mutation [25]. Our 61 year-old patient was a sporadic case with a clinical phenotype resembling that of the patient reported by Belzil et al., being primarely characterized by spinal ALS without evidence of cognitive impairment [24].
Two patients (1%) carried previously described Class-5 heterozygous VCP variants: the p.Arg93Cys [26,27] and the p.Arg155Cys [28,29]. Mutations in the valosin-containing protein, an ATPase involved in protein degradation and autophagy, have previously been identified in families with inclusion body myopathy, Paget’s disease, and frontotemporal dementia (IBMPFD, MIM:167320). Johnson et al. [40] described for the first time VCP mutations in ALS cases, including patients belonging to a four-generation Italian family. In a cohort of 231 individuals carrying VCP mutations, Al-Obeidi et al. reported myopathy in 90% of patients, Paget’s disease of bone in 42%, frontotemporal dementia in 30%, and ALS phenotype in approximately 9% of patients [41]. The phenotype in our two cases was consistent with previously described patients with unequivocal upper and lower motor neuron involvement, at the ages of 47 and 42 years, without FTD or Paget’s disease. The VCP p.Arg93Cys variant, identified in patient P072, was previously reported in a 70-year-old patient with a diagnosis of distal myopathy and rimmed vacuoles [27], and in several subjects from a single family in which three subjects presented cognitive impairement and myopathy, and three others had Paget’s disease [26]. In our case, the mother and two maternal uncles were diagnosed with Alzheimer disease, and a brother had the diagnosis of ALS and Paget disease. The second Class-5 VCP variant (p.Arg155Cys) was also reported in several families with IBMPFD [28,29]. The clinical phenotype of our patient (P008) was characterized by progressive motor neuron impairement and, interestingly, rimmed vacules at muscle biopsy morphological evaluation.
The third gene responsible for ALS disease in our study was SQSTM1 (1%). Also, this gene has been associated with a wide spectrum of phenotypes. In 2002, a recurrent non-conservative change in SQSTM1 (p.Pro392Leu) was reported in a high proportion of French Canadian patients affected by Paget disease [42]. Subsequently heterozygous mutations in SQSTM1 were reported in patients presenting ALS, in patients with ALS, and FTD or Paget disease, and in a patient with isolated distal rimmed-vacuole myopathy [43,44,45,46,47]. In our SQSTM1 mutated patients, the clinical phenotype was characterized by typical ALS disease, with no signs of bone abnormalities or FTD.
Finally, pathogenic variants were identified in the autosomal dominant genes SETX (0.4%), FIG4 (0.4%), and GARS1 (0.4%). Heterozygous missense variants in SETX were suggested to cause a rare autosomal dominant form of juvenile ALS (MIM:602433) with onset <25 years and a slow rate of disease progression [48]. In our cohort, we identified seven SETX gene variants: six were classified as VUS, and the p.Met917Thr variant was classified as likely pathogenic (Class-4) because already reported in an ALS patient [5]. The authentic contribution of this variant to ALS disease, as well as for other SETX heterozygous variants reported in ALS, remains to be further investigated and proven. The p.Met917Thr SETX variant is reported in population databases, and in our case, was associated with a late onset and rapidly progressive ALS phenotype. In several NGS studies, there is an abundance of SETX variants, mostly identified in sporadic with the typical late-onset ALS phenotype [5,35,49]. Due to the relatively high detection rate of heterozygous SETX variants both in patients and controls, it is still controversial if this gene may contribute to a substantial proportion of genetic ALS or if it should be rather considered as a susceptibility genetic factor. A clear pathogenic role is demonstrated for biallelic mutations in SETX for a recessive form of cerebellar ataxia with oculomotor apraxia type 2 (AOA2, MIM:606002). In AOA2 families, an increase incidence of ALS disease in SETX heterozygous family members has not been reported.
GARS1 and FIG4 genes are both associated with either ALS or hereditary neuropathy [31,50,51,52]. Clinical and neurophysiological data of our patients confirmed the involvement of both upper and lower motor neurons, supporting the association with the ALS phenotype.
We also reported the identification of 49 novel or rare variants in 19 different genes, whose pathogenetic significance could not be presently determined. These VUS involved 30 patients for which genetic counseling remains challenging and genetic informations might need periodic reevaluation. The same difficulties can be shared for the 48 variant identified in ALS susceptibility genes. For ATXN2, we describe missense variants, but an increased risk of developing ALS disease has been associated, so far, only with alleles carrying long sequences of repeated CAG triplets [53]. Thus, the possible role in ALS susceptibility for rare missense variants within other coding regions is not yet defined. With the advent of NGS technology, an increasingly number of rare genetic variants are being identified in known ALS genes and the genetic architecture of ALS is emerging in all its complexity. Even though the use of a targeted panel is cost effective to screen a large list of genes, the classification of all identified variants and segregation studies are critical procedures requiring time and resources. For timely diagnoses and genetic counseling, it could be useful to consider the reported frequencies of causative genes to prioritize the analyses of rare pathogenic variants.
The results of our study highlight the relative contribution of OPTN, VCP, and SQSTM1 variants in rare forms of genetic ALS, suggesting the screening of these genes during routine diagnostic investigations in both sporadic and familial ALS cases.

Supplementary Materials

The following are available online at https://www.mdpi.com/2077-0383/9/2/412/s1, Table S1: Reference sequences for transcript (NM) and protein (NP) of genes analyzed in the study; Table S2: Criteria applied in the classification of variants identified in ALS genes; Table S3: Gene variants in ALS susceptibility genes; Table S4: Heterozygous gene variants in autosomal recessive ALS genes; Table S5: Class-2 gene variants.

Author Contributions

Conceptualization: G.L. and C.G.; Data curation: V.P., S.M., E.D.B., P.T., M.G., G.S. and C.M.; Formal analysis: S.M. and C.G.; Funding acquisition: G.L.and C.G.; Investigation: V.P., E.D.B., P.T., E.B., G.S., N.T.and C.M.; Methodology:V.P., S.M., M.G. and F.T.; Supervision: N.T., F.T., G.L. and C.G.; Writing—original draft: C.M. and C.G.; Writing—review & editing: M.G., F.T., G.L., C.M. and C.G. All authors have read and agreed to the published version of the manuscript.

Acknowledgments

The authors wish to thank all the Italian ALS patients participating in the study and their caregivers for support. V.P.; P.T. and C.G. have been partially supported for this work by Fondazione Regionale per la Ricerca Biomedica (Regione Lombardia, Grant FRRB 2015-0023 to G.L.) and by the Italian Ministry of Health (Grant RF 2013-02355764 to CG).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hardiman, O.; Al-Chalabi, A.; Chio, A.; Corr, E.M.; Logroscino, G.; Robberecht, W.; Shaw, P.J.; Simmons, Z.; Van Den Berg, L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 2017, 3, 17071. [Google Scholar] [CrossRef]
  2. Al-Chalabi, A.; Hardiman, O.; Kiernan, M.C.; Chiò, A.; Rix-Brooks, B.; Van Den Berg, L.H. Amyotrophic lateral sclerosis: Moving towards a new classification system. Lancet Neurol. 2016, 15, 1182–1194. [Google Scholar] [CrossRef]
  3. Brown, R.H.; Al-Chalabi, A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2017, 377, 162–172. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Renton, A.E.; Chiò, A.; Traynor, B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014, 17, 17–23. [Google Scholar] [CrossRef] [PubMed]
  5. Cady, J.; Allred, P.; Bali, T.; Pestronk, A.; Goate, A.; Miller, T.M.; Mitra, R.D.; Ravits, J.; Harms, M.B.; Baloh, R.H. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann. Neurol. 2015, 77, 100–113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.; O’Regan, J.P.; Deng, H.X.; et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362, 59–62. [Google Scholar] [CrossRef]
  7. Su, X.W.; Broach, J.R.; Connor, J.R.; Gerhard, G.S.; Simmons, Z. Genetic heterogeneity of amyotrophic lateral sclerosis: Implications for clinical practice and research. Muscle Nerve 2014, 49, 786–803. [Google Scholar] [CrossRef]
  8. Al-Chalabi, A.; Hardiman, O. The epidemiology of ALS: A conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013, 9, 617–628. [Google Scholar] [CrossRef]
  9. Cruts, M.; Gijselinck, I.; Van Langenhove, T.; van der Zee, J.; Van Broeckhoven, C. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci. 2013, 36, 450–459. [Google Scholar] [CrossRef]
  10. Ratti, A.; Corrado, L.; Castellotti, B.; Del Bo, R.; Fogh, I.; Cereda, C.; Tiloca, C.; D’Ascenzo, C.; Bagarotti, A.; Pensato, V.; et al. C9ORF72 repeat expansion in a large Italian ALS cohort: Evidence of a founder effect. Neurobiol. Aging 2012, 33, 2528.e7–2528.e14. [Google Scholar] [CrossRef]
  11. Sreedharan, J.; Blair, I.P.; Tripathi, V.B.; Hu, X.; Vance, C.; Rogelj, B.; Ackerley, S.; Durnall, J.C.; Williams, K.L.; Buratti, E.; et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319, 1668–1672. [Google Scholar] [CrossRef] [PubMed]
  12. Kwiatkowski, T.J.; Bosco, D.A.; Leclerc, A.L.; Tamrazian, E.; Vanderburg, C.R.; Russ, C.; Davis, A.; Gilchrist, J.; Kasarskis, E.J.; Munsat, T.; et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323, 1205–1208. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Corrado, L.; Ratti, A.; Gellera, C.; Buratti, E.; Castellotti, B.; Carlomagno, Y.; Ticozzi, N.; Mazzini, L.; Testa, L.; Taroni, F.; et al. High frequency of TARDBP gene mutations in italian patients with amyotrophic lateral sclerosis. Hum. Mutat. 2009, 30, 688–694. [Google Scholar] [CrossRef] [PubMed]
  14. Corrado, L.; Del Bo, R.; Castellotti, B.; Ratti, A.; Cereda, C.; Penco, S.; Sorarù, G.; Carlomagno, Y.; Ghezzi, S.; Pensato, V.; et al. Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. J. Med. Genet. 2010, 47, 190–194. [Google Scholar] [CrossRef]
  15. Ticozzi, N.; Silani, V.; LeClerc, A.L.; Keagle, P.; Gellera, C.; Ratti, A.; Taroni, F.; Kwiatkowski, T.J.; McKenna-Yasek, D.M.; Sapp, P.C.; et al. Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort. Neurology 2009, 73, 1180–1185. [Google Scholar] [CrossRef] [Green Version]
  16. Marangi, G.; Traynor, B.J. Genetic causes of amyotrophic lateral sclerosis: New genetic analysis methodologies entailing new opportunities and challenges. Brain Res. 2015, 1607, 75–93. [Google Scholar] [CrossRef] [Green Version]
  17. Al-Chalabi, A.; Calvo, A.; Chio, A.; Colville, S.; Ellis, C.M.; Hardiman, O.; Heverin, M.; Howard, R.S.; Huisman, M.H.B.; Keren, N.; et al. Analysis of amyotrophic lateral sclerosis as a multistep process: A population-based modelling study. Lancet Neurol. 2014, 13, 1108–1113. [Google Scholar] [CrossRef]
  18. Chiò, A.; Mazzini, L.; D’Alfonso, S.; Corrado, L.; Canosa, A.; Moglia, C.; Manera, U.; Bersano, E.; Brunetti, M.; Barberis, M.; et al. The multistep hypothesis of ALS revisited: The role of genetic mutations. Neurology 2018, 91, e635–e642. [Google Scholar] [CrossRef] [Green Version]
  19. Campanari, M.-L.; Bourefis, A.-R.; Kabashi, E. Diagnostic challenge and neuro-muscular junction contribution to ALS pathogenesis. Front. Neurol. 2019, 10, 68. [Google Scholar] [CrossRef] [Green Version]
  20. Al-Chalabi, A.; Van Den Berg, L.H.; Veldink, J. Gene discovery in amyotrophic lateral sclerosis: Implications for clinical management. Nat. Rev. Neurol. 2017, 13, 96–104. [Google Scholar] [CrossRef] [Green Version]
  21. Antoniadi, T.; Buxton, C.; Dennis, G.; Forrester, N.; Smith, D.; Lunt, P.; Burton-Jones, S. Application of targeted multi-gene panel testing for the diagnosis of inherited peripheral neuropathy provides a high diagnostic yield with unexpected phenotype-genotype variability. BMC Med. Genet. 2015, 16, 84. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Del Bo, R.; Tiloca, C.; Pensato, V.; Corrado, L.; Ratti, A.; Ticozzi, N.; Corti, S.; Castellotti, B.; Mazzini, L.; Sorarù, G.; et al. Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 2011, 82, 1239–1243. [Google Scholar] [CrossRef] [PubMed]
  23. Black, H.A.; Leighton, D.J.; Cleary, E.M.; Rose, E.; Stephenson, L.; Colville, S.; Ross, D.; Warner, J.; Porteous, M.; Gorrie, G.H.; et al. Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. Neurobiol. Aging 2017, 51, e11–e178. [Google Scholar] [CrossRef] [PubMed]
  24. Belzil, V.V.; Daoud, H.; Desjarlais, A.; Bouchard, J.P.; Dupré, N.; Camu, W.; Dion, P.A.; Rouleau, G.A. Analysis of OPTN as a causative gene for amyotrophic lateral sclerosis. Neurobiol. Aging 2011, 32, 555.e13–555.e14. [Google Scholar] [CrossRef] [PubMed]
  25. Pottier, C.; Bieniek, K.F.; Finch, N.C.; van de Vorst, M.; Baker, M.; Perkersen, R.; Brown, P.; Ravenscroft, T.; van Blitterswijk, M.; Nicholson, A.M.; et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 2015, 130, 77–92. [Google Scholar] [CrossRef]
  26. Guyant-Maréchal, L.; Laquerrière, A.; Duyckaerts, C.; Dumanchin, C.; Bou, J.; Dugny, F.; Le Ber, I.; Frébourg, T.; Hannequin, D.; Campion, D. Valosin-containing protein gene mutations: Clinical and neuropathologic features. Neurology 2006, 67, 644–651. [Google Scholar] [CrossRef]
  27. Shi, Z.; Hayashi, Y.K.; Mitsuhashi, S.; Goto, K.; Kaneda, D.; Choi, Y.C.; Toyoda, C.; Hieda, S.; Kamiyama, T.; Sato, H.; et al. Characterization of the Asian myopathy patients with VCP mutations. Eur. J. Neurol. 2012, 19, 501–509. [Google Scholar] [CrossRef]
  28. Stojkovic, T.; Hammouda, E.H.; Richard, P.; de Munain, A.L.; Ruiz-Martinez, J.; Gonzalez, P.C.; Laforêt, P.; Pénisson-Besnier, I.; Ferrer, X.; Lacour, A.; et al. Clinical outcome in 19 French and Spanish patients with valosin-containing protein myopathy associated with Paget’s disease of bone and frontotemporal dementia. Neuromuscul. Disord. 2009, 19, 316–323. [Google Scholar] [CrossRef]
  29. Watts, G.D.J.; Wymer, J.; Kovach, M.J.; Mehta, S.G.; Mumm, S.; Darvish, D.; Pestronk, A.; Whyte, M.P.; Kimonis, V.E. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 2004, 36, 377–381. [Google Scholar] [CrossRef]
  30. Bertolin, C.; Querin, G.; Bozzoni, V.; Martinelli, I.; De Bortoli, M.; Rampazzo, A.; Gellera, C.; Pegoraro, E.; Sorarù, G. New FIG4 gene mutations causing aggressive ALS. Eur. J. Neurol. 2018, 25, e41–e42. [Google Scholar] [CrossRef]
  31. Chow, C.Y.; Zhang, Y.; Dowling, J.J.; Jin, N.; Adamska, M.; Shiga, K.; Szigeti, K.; Shy, M.E.; Li, J.; Zhang, X.; et al. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 2007, 448, 68–72. [Google Scholar] [CrossRef] [PubMed]
  32. Nicholson, G.; Lenk, G.M.; Reddel, S.W.; Grant, A.E.; Towne, C.F.; Ferguson, C.J.; Simpson, E.; Scheuerle, A.; Yasick, M.; Hoffman, S.; et al. Distinctive genetic and clinical features of CMT4J: A severe neuropathy caused by mutations in the PI(3,5)P 2 phosphatase FIG4. Brain 2011, 134, 1959–1971. [Google Scholar] [CrossRef] [Green Version]
  33. Zou, Z.Y.; Zhou, Z.R.; Che, C.H.; Liu, C.Y.; He, R.L.; Huang, H.P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 2017, 88, 540–549. [Google Scholar] [CrossRef] [PubMed]
  34. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and Guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [Google Scholar] [CrossRef] [PubMed]
  35. Kenna, K.P.; McLaughlin, R.L.; Byrne, S.; Elamin, M.; Heverin, M.; Kenny, E.M.; Cormican, P.; Morris, D.W.; Donaghy, C.G.; Bradley, D.G.; et al. Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing. J. Med. Genet. 2013, 50, 776–783. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Müller, K.; Brenner, D.; Weydt, P.; Meyer, T.; Grehl, T.; Petri, S.; Grosskreutz, J.; Schuster, J.; Volk, A.E.; Borck, G.; et al. Comprehensive analysis of the mutation spectrum in 301 German ALS families. J. Neurol. Neurosurg. Psychiatry 2018, 89, 817–827. [Google Scholar] [CrossRef] [PubMed]
  37. Morgan, S.; Shoai, M.; Fratta, P.; Sidle, K.; Orrell, R.; Sweeney, M.G.; Shatunov, A.; Sproviero, W.; Jones, A.; Al-Chalabi, A.; et al. Investigation of next-generation sequencing technologies as a diagnostic tool for amyotrophic lateral sclerosis. Neurobiol. Aging 2015, 36, 1600.e5–1600.e8. [Google Scholar] [CrossRef]
  38. Nishiyama, A.; Niihori, T.; Warita, H.; Izumi, R.; Akiyama, T.; Kato, M.; Suzuki, N.; Aoki, Y.; Aoki, M. Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis. Neurobiol. Aging 2017, 53, 194.e1–194.e8. [Google Scholar] [CrossRef]
  39. Maruyama, H.; Morino, H.; Ito, H.; Izumi, Y.; Kato, H.; Watanabe, Y.; Kinoshita, Y.; Kamada, M.; Nodera, H.; Suzuki, H.; et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465, 223–226. [Google Scholar] [CrossRef]
  40. Johnson, J.O.; Mandrioli, J.; Benatar, M.; Abramzon, Y.; Van Deerlin, V.M.; Trojanowski, J.Q.; Gibbs, J.R.; Brunetti, M.; Gronka, S.; Wuu, J.; et al. Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron 2010, 68, 857–864. [Google Scholar] [CrossRef] [Green Version]
  41. Al-Obeidi, E.; Al-Tahan, S.; Surampalli, A.; Goyal, N.; Wang, A.K.; Hermann, A.; Omizo, M.; Smith, C.; Mozaffar, T.; Kimonis, V. Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy. Clin. Genet. 2018, 93, 119–125. [Google Scholar] [CrossRef]
  42. Laurin, N.; Brown, J.P.; Morissette, J.; Raymond, V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in paget disease of bone. Am. J. Hum. Genet. 2002, 70, 1582–1588. [Google Scholar] [CrossRef] [Green Version]
  43. Fecto, F.; Yan, J.; Vemula, S.P.; Liu, E.; Yang, Y.; Chen, W.; Zheng, J.G.; Shi, Y.; Siddique, N.; Arrat, H.; et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2011, 68, 1440–1446. [Google Scholar] [CrossRef]
  44. Rubino, E.; Rainero, I.; Chio, A.; Rogaeva, E.; Galimberti, D.; Fenoglio, P.; Grinberg, Y.; Isaia, G.; Calvo, A.; Gentile, S.; et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 2012, 79, 1556–1562. [Google Scholar] [CrossRef] [Green Version]
  45. Hirano, M.; Nakamura, Y.; Saigoh, K.; Sakamoto, H.; Ueno, S.; Isono, C.; Miyamoto, K.; Akamatsu, M.; Mitsui, Y.; Kusunoki, S. Mutations in the gene encoding p62 in Japanese patients with amyotrophic lateral sclerosis. Neurology 2013, 80, 458–463. [Google Scholar] [CrossRef]
  46. Le Ber, I.; Camuzat, A.; Guerreiro, R.; Bouya-Ahmed, K.; Bras, J.; Nicolas, G.; Gabelle, A.; Didic, M.; De Septenville, A.; Millecamps, S.; et al. SQSTM1 Mutations in french patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol. 2013, 70, 1403–1410. [Google Scholar]
  47. Bucelli, R.C.; Arhzaouy, K.; Pestronk, A.; Pittman, S.K.; Rojas, L.; Sue, C.M.; Evilä, A.; Hackman, P.; Udd, B.; Harms, M.B.; et al. SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles. Neurology 2015, 85, 665–674. [Google Scholar] [CrossRef] [Green Version]
  48. Chen, Y.Z.; Bennett, C.L.; Huynh, H.M.; Blair, I.P.; Puls, I.; Irobi, J.; Dierick, I.; Abel, A.; Kennerson, M.L.; Rabin, B.A.; et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 2004, 74, 1128–1135. [Google Scholar] [CrossRef] [Green Version]
  49. Hirano, M.; Quinzii, C.M.; Mitsumoto, H.; Hays, A.P.; Roberts, J.K.; Richard, P.; Rowland, L.P. Senataxin mutations and amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2011, 12, 223–227. [Google Scholar] [CrossRef]
  50. Chow, C.Y.; Landers, J.E.; Bergren, S.K.; Sapp, P.C.; Grant, A.E.; Jones, J.M.; Everett, L.; Lenk, G.M.; McKenna-Yasek, D.M.; Weisman, L.S.; et al. Deleterious Variants of FIG4, a Phosphoinositide Phosphatase, in Patients with ALS. Am. J. Hum. Genet. 2009, 84, 85–88. [Google Scholar] [CrossRef] [Green Version]
  51. Antonellis, A.; Ellsworth, R.E.; Sambuughin, N.; Puls, I.; Abel, A.; Lee-Lin, S.-Q.; Jordanova, A.; Kremensky, I.; Christodoulou, K.; Middleton, L.T.; et al. Glycyl tRNA Synthetase Mutations in Charcot-Marie-Tooth Disease Type 2D and Distal Spinal Muscular Atrophy Type V. Am. J. Hum. Genet. 2003, 72, 1293–1299. [Google Scholar] [CrossRef] [Green Version]
  52. Corcia, P.; Brulard, C.; Beltran, S.; Marouillat, S.; Bakkouche, S.E.; Andres, C.R.; Blasco, H.; Vourc’h, P. Typical bulbar ALS can be linked to GARS mutation. Amyotroph. Lateral Scler. Front. Degener. 2019, 20, 275–277. [Google Scholar] [CrossRef]
  53. Sproviero, W.; Shatunov, A.; Stahl, D.; Shoai, M.; van Rheenen, W.; Jones, A.R.; Al-Sarraj, S.; Andersen, P.M.; Bonini, N.M.; Conforti, F.L.; et al. ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol. Aging 2017, 51, 178.e1–178.e9. [Google Scholar] [CrossRef]
Jcm 09 00412 g001 550
Figure 1. Gene variants and their estimated pathogeneicity class in a cohort of 213 Italian ALS patients tested negative for the most frequent ALS causative genes. Values represent the relative contribution of mutations in ALS genes, other motor neuron disease genes, and gene associated with frontotemporal dementia (FTD).
Figure 1. Gene variants and their estimated pathogeneicity class in a cohort of 213 Italian ALS patients tested negative for the most frequent ALS causative genes. Values represent the relative contribution of mutations in ALS genes, other motor neuron disease genes, and gene associated with frontotemporal dementia (FTD).
Jcm 09 00412 g001
Table
Table 1. Genes analyzed in this study.
Table 1. Genes analyzed in this study.
ALSGeneProteinDisease[OMIM] Inherit.
ALS1SOD1Superoxide Dismutase [Cu-Zn]Amyotrophic lateral sclerosis 1 [MIM:105400]AD
Amyotrophic lateral sclerosis 1 [MIM:105400] D90A; D96N AR
ALS2ALS2AlsinAmyotrophic lateral sclerosis 2 [MIM:205100] AR
Infantile-onset ascending spastic paralysis (IAHSP) [MIM:607225]AR
Juvenile primary lateral sclerosis (JPLS) [MIM:606353]AR
ALS4SETXProbable helicase senataxinAmyotrophic lateral sclerosis 4, juvenile ALS [MIM:602433]AD
Spinocerebellar ataxia, 1 (SCAR1) [MIM:606002]AR
ALS5SPG11SpatacsinAmyotrophic lateral sclerosis 5, juvenile [MIM:602099]AR
Charcot–Marie–Tooth disease, axonal type 2X(CMT2X) [MIM:616668]AR
Spastic paraplegia 11, (SPG11) [MIM:604360]AR
ALS6FUSRNA-binding protein FUSAmyotrophic lateral sclerosis 6, +/- FTD [MIM:608030]AD
Tremor, hereditary essential 4 (ETM4) [MIM:614782]AD
ALS8VAPBVesicle-associated membrane protein-B/CAmyotrophic lateral sclerosis 8 [MIM:608627]AD
Spinal muscular atrophy, late-onset, (SMAFK) [MIM:182980]AD
ALS9ANGAngiogeninAmyotrophic lateral sclerosis 9; [MIM:611895]AD
ALS10TARDBPTAR DNA-binding protein 43Amyotrophic lateral sclerosis 10, +/- FTD [MIM:612069]AD
ALS11FIG4Polyphospho inositide phosphataseAmyotrophic lateral sclerosis 11 [MIM:612577]AD
Charcot–Marie–Tooth disease 4J (CMT4J) [MIM:611228]AR
Polymicrogyria, bilateral temporooccipital (BTOP) [MIM:612691]AR
ALS12OPTNOptineurinAmyotrophic lateral sclerosis 12 [MIM:613435]AR/AD
Glaucoma 1, open angle, E (GLC1E) [MIM:137760]AD
ALS14VCPTransitional endoplasmic reticulum ATPaseAmyotrophic lateral sclerosis 14, +/- FTD [MIM:613954]AD
Charcot–Marie–Tooth disease, type 2Y (CMT2Y) [MIM:616687]AD
Inclusion body myopathy with Paget disease +/- FTD [MIM:167320]AD
ALS15UBQLN2Ubiquilin-2Amyotrophic lateral sclerosis 15, +/- FTD [MIM:300857]XLD
ALS16SIGMAR1Sigma non-opioid intracellular receptor 1Amyotrophic lateral sclerosis 16, juvenile [MIM:614373]AR
Distal spinal muscular atrophy, 2 (DSMA2) [MIM:605726]AR
ALS17CHMP2BCharged multivesicular body protein 2bAmyotrophic lateral sclerosis 17 [MIM:614696]AD
FTD chromosome 3-linked (FTD3) [MIM:600795]AD
ALS18PFN1Profilin-1Amyotrophic lateral sclerosis 18 [MIM:614808]AD
ALS19ERBB4Receptor tyrosine-protein kinase erbB-4Amyotrophic lateral sclerosis 19 [MIM:615515]AD
ALS20HNRNPA1Heterogeneous nuclear ribonucleoprotein A1Amyotrophic lateral sclerosis 20 [MIM:615426]AD
Inclusion body myopathy with Paget disease +/- FTD3 [MIM:615424]AD
ALS21MATR3Matrin-3Amyotrophic lateral sclerosis 21 [MIM:606070]AD
ALS22TUBA4ATubulin alpha-4A chainAmyotrophic lateral sclerosis 22, +/- FTD [MIM:616208]AD
FTDALS2CHCHD10Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrialFTD +/- amyotrophic lateral sclerosis 2 [MIM:615911]AD
Isolated Mitochondrial Myopathy (IMMD) [MIM:616209]AD
Spinal muscular atrophy, Jokela type (SMAJ) [MIM:615048]AD
FTDALS3SQSTM1Sequestosome-1FTD +/- amyotrophic lateral sclerosis 3 [MIM:616437]AD
Ataxia, dystonia, gaze palsy[MIM:617145]AR
Myopathy distal, with rimmed vacuoles [MIM:617158]AD
Paget disease of bone 3 (PDB3) [MIM:167250]AD
ALS suscepATXN2Ataxin-2{Amyotrophic lateral sclerosis, susceptibility to, 13} [MIM:183090]AD
Spinocerebellar ataxia 2 (SCA2) [MIM:183090]AD
ALS suscepAPEX1apurinic/apyrimidinic endodeoxyribonuclease1
ALS suscepCRYMKetimine reductase mu-crystallinDeafness, autosomal dominant 40 (DFNA40) [MIM:616357]AD
ALS suscepCYP27A1Sterol 26-hydroxylase,Cerebrotendinous xanthomatosis (CTX) [MIM:213700]AR
ALS suscepDAOD-amino-acid oxidase
ALS suscepDCTN1Dynactin subunit 1{Amyotrophic lateral sclerosis, susceptibility to} [MIM:105400]
Neuronopathy, distal hereditary motor, 7B (HMN7B) [MIM:607641]AD
Perry syndrome (PERRYS) [MIM:168605]AD
ALS suscepDPP6Dipeptidyl-aminope-peptidase-like protein 6Mental retardation, autosomal dominant 33 (MRD33) [MIM:616311]AD
ALS suscepELP3Elongator Acetyltransferase Complex Subunit 3
ALS suscepEPHA4Ephrin type-A receptor 4
ALS suscepHNRNPA2B1Heterogeneous nuclear ribonucleoproteinsA2/B1Inclusion body myopathy and Paget disease +/- FTD [MIM:615422]
ALS suscepHNRNPA3Heterogeneous nuclear ribonucleo-protein A3
ALS suscepNEFHNeurofilament heavy polypeptide{Amyotrophic lateral sclerosis, susceptibility to} [MIM:105400]
Charcot–Marie–Tooth, axonal, type 2CC (CMT2CC) [MIM:616924]AD
ALS suscepNEK1Serine/threonine-protein kinase Nek1Short-rib thoracic dysplasia 6 +/- polydactyly(SRTD6) [MIM:263520]AR
ALS suscepTAF15TATA-binding protein-associated factor 2NChondrosarcoma, extraskeletal myxoid [MIM:612237]
ALS suscepTREM2Triggering receptor expressed myeloid cells2Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) [MIM:221770]AR
FTDGRNGranulinsFTD with ubiquitin-positive inclusions ([MIM:607485]AD
Aphasia, primary progressive [MIM:607485]AD
Ceroid lipofuscinosis, neuronal, 11 (CLN11) [MIM:614706]AR
FTDMAPTMicrotubule-associated protein tauFrontotemporal dementia (FTD) [MIM:600274]AD
Pick disease of the brain (PIDB) [MIM:172700]AD
Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]AD
Parkinson-dementia syndrome (PARDE) [MIM:260540]AR
SMAASAH1Acid ceramidaseFarber lipogranulomatosis (FRBRL) [MIM:228000] AR
Spinal muscular atrophy, progressive myoclonic epilepsy[MIM:159950]AR
HMN/HSPBSCL2SeipinLipodystrophy congenital generalized type 2 (CGL2) [MIM:269700]AR
Encephalopathy progressive, +/- lipodystrophy (PELD) [MIM:615924]AR
Neuronopathy, distal hereditary motor, 5A (HMN5A) [MIM:600794]AD
Spastic paraplegia 17, (SPG17) [MIM:270685]AD
HMNGARS1Glycyl-tRNA synthetase 1 Charcot-Marie-Tooth disease 2D (CMT2D) [MIM:601472]AD
Neuronopathy, distal hereditary motor, 5A (HMN5A) [MIM:600794]AD
HMNIGHMBP2Immunoglobulin mu-binding protein 2 Charcot–Marie–Tooth disease 2S (CMT2S) [MIM:616155]AR
Neuronopathy, distal hereditary motor, 6 (HMN6) [MIM:604320]AR
HMN/HSPPNPLA6Neuropathy target esteraseBoucher–Neuhauser syndrome (BNHS) [MIM:215470]AR
Laurence-Moon [MIM:245800];Oliver-McFarlane [MIM:275400]AR
Spastic paraplegia 39 (SPG39) [MIM:612020]AR
Neuronopathy, distal hereditary motor, 5B (HMN5B) [MIM:614751]AR
HSPREEP1Receptor expression-enhancing protein1Spastic paraplegia 31 (SPG31) [MIM:610250]AD
HSPSPASTSpastinSpastic paraplegia 4 (SPG4) [MIM:182601]AD
HMNTRPV4Transient receptor potential cation channel subfamily V4Digital arthropathy-brachydactyly, familial (FDAB) [MIM:606835]AD
Neuronopathy, distal hereditary motor, 8 (HMN8) [MIM:600175]AD
Scapuloperoneal spinal muscular atrophy (SPSMA) [MIM:181405]AD
ALS suscep: amyotrophic lateral sclerosis susceptibility genes; SMA: spinal muscular atrophy; HMN: hereditary motor neuronopathy; HSP: hereditary spastic paraplegia; FTD frontotemporal dementia; MIM, Mendelian Inheritance in Man; IBMPFD inclusion body myopathy and Paget disease +/- FTD; AD, autosomal dominant; AR, autosomal recessive; XLD, X-linked dominant. +/- with or without.
Table
Table 2. Summary of identified gene variants and classes of pathogenicity.
Table 2. Summary of identified gene variants and classes of pathogenicity.
GeneN. of VariantsClass 5Class 4Class 3Class 2Recurrent Variants
ALS (AD)ANG4 13 ** 1 recurrent in 3 pts
CHCHD100
CHMP2B1 1
ERBB44 22 ** 1 recurrent in 2 pts
FIG44112
HNRNPA10
MATR31 1
OPTN32 1
PFN10
SETX21 1614 ** 1 recurrent in 7 pts
* 1 recurrent in 5 pts
SQSTM16 213 ** 1 recurrent in 3 pts
TUBA4A0
VAPB3 3 ** 1 recurrent in 3 pts
VCP42 2
ALS (XLD)UBQLN21 1
ALS (AR)ALS24 13
SIGMAR11 1
SPG117 34
HMN/HSP(AD)BSCL20
GARS19 15 §3 *§ 1 recurrent in 3 pts
* 1 recurrent in 3 pts
REEP10
TRPV49 36 ** 1 recurrent in 3 pts
SPAST1 1
SMA/HMN/HSP(AR)ASAH131 2
IGHMBP2104141
PNPLA661 5
FTD (AD)GRN8 44** 1 recurrent in 4 pts
MAPT2 2
Total 112118494410 recurrent variants
(9 Class-2, 1 Class-3)
Specific DNA and protein variants of Classes 3-4-5 are listed in Table 4; Table 5. Class-2 variants are listed in Supplementary Table S5. §: recurrent variants of class 3; *: recurrent variants of class 2.
Table
Table 3. Total gene variants identified in amyotrophic lateral sclerosis (ALS) susceptibility genes.
Table 3. Total gene variants identified in amyotrophic lateral sclerosis (ALS) susceptibility genes.
GeneNumber of Variants
ALS susceptibility genesAPEX1
ATXN214 ** 1 recurrent in 2 pts
* 1 recurrent in 7 pts
CRYM2 ** 1 recurrent in 2 pts
CYP27A14
DAO1
DCTN110 ** 1 recurrent in 3 pts
DPP61
ELP32
EPHA42
HNRNPA2B1
HNRNPA35 ** 1 recurrent in 3 pts
NEFH4 ** 1 recurrent in 4 pts
NEK11
TAF15
TREM22
Total486 recurrent variants
Specific DNA and protein variants in susceptibility genes are listed in Supplementary Table S3. *: recurrent variants.
Table
Table 4. Pathogenic and likely pathogenic variants in ALS genes (Classes 4 and 5).
Table 4. Pathogenic and likely pathogenic variants in ALS genes (Classes 4 and 5).
GeneClassVariant
DNA		Variant
Protein		MAF % *dbSNPAdditional VariantsClinical NotesPatientRef.
OPTN5c.941A>Tp.Gln314Leu0%-0.02%-0.01%rs142812715(AR) ALS2: c.331G>A (p.Val111Ile) het [rs61745503, MAF *: 0.04%-0.02%-0.03%] (Class3)Bulbar-Spinal ALS laboratory supportedP087[22,23]
OPTN5c.1442C>Tp.Ala481Val0%-0.01%-0%rs377219791 Spinal ALS-laboratory supportedP015[24,25]
VCP5c.277C>Tp.Arg93Cys0%-0%-0% Spinal ALS, no FTD, no PagetP072[26,27]
VCP5c.463C>Tp.Arg155Cys0%-0%-0%rs121909330(AR) IGHMBP2: c.2911_2912delAG (p.Arg971GlufsTer4) het [rs572973851; rs724159994, MAF *: 0%-0.82%-0.02%] (Class5)Spinal ALS, no FTD, no PagetP008[28,29]
SQSTM14c.695C>Tp.Pro232Leu0%-0%-0%rs757778292(Suscep.) DAO: c.627G>A (p.Trp209Ter) het [rs766258671, MAF*: 0%-0%-0% ]
(Suscep.) DCTN1: c.652G>A(p.Glu218Lys) het [MAF *: 0%-0%-0%]		Bulbar ALS, onset 43 yearsP002
SQSTM14c.301 + 4delAp.? HSF: Alteration of the WT donor site, most probably affecting splicing.0%-0%-0% (AR) IGHMBP2: c.2176G>A (p.Val726Met) het [rs143986510, MAF *: 0.02%-0.08%-0.04%] (Class3)ALSP103
FIG45
4		c.122T>C
c.1667C>T		p.Ile41Thr
p.Thr556Ile		0.08%-0.11%-0.1%
0%-0%-0%		rs121908287
 Juvenile ALS with predominant upper motor neuron involvementP100[30]
SETX4c.2750T>Cp.Met917Thr0%-0.01%-0.01%rs376022544 ALSP022[5]
GARS14c.1955G>Ap.Gly652Glu0%-0%-0%rs747080824 ALS
Pseudo-polyneuritic type		P073
* MAF (minor allele frequency) % in 1000Genomes-Go-ESP-ExAC. Het: heterozygous; HSF: Human Splicing Finder; (Suscep.): variants in ALS susceptibility genes; (AR): variants in autosomal recessive genes.
Table
Table 5. Variants of unknown significance (VUS) in ALS/HMN/FTD genes (Class 3).
Table 5. Variants of unknown significance (VUS) in ALS/HMN/FTD genes (Class 3).
GeneClassVariant
DNA		Variant
Protein		MAF % *dbSNPAdditional VariantsClinical NotesPatient
OPTN3c.910C>Tp.Leu304Phe0%-0%-0% (Suscep.) ATXN2: c.3000A > G (p =) het [rs140262591, MAF *: 0.2%-0.31%-0.3%]Spinal ALSP075
VCP3c.179A>Gp.Lys60Arg0%-0%-0% (Suscep.) ATXN2: c.3322C > T (p.Pro1108Ser) het [rs140242317, MAF *: 0.04%-0.11%-0.07% ]Slowly progressive ALS with cognitive impairmentP112
VCP3c.1696-3C>Tp.?0%-0.01%-0.01%rs372638909 Rapidly progressive ALS with cognitive impairmentP025
FIG43c.646G>Ap.Gly216Arg0%-0%-0%rs759566206(Class 2) SQSTM1: c.712A > G (p.Lys238Glu) het [rs11548633, MAF *: 0.24%-0.26%-0.24%]Progressive muscular weakness and sensory neuropathyP105
FIG43c.1243C>Gp.Pro415Ala0%-0%-0% (Class 3) GARS1: c.302G > A (p.Arg101His) het [rs200887429, MAF *: 0.02%-0.02%-0.04%];
(Class 2) SETX: c.4660T > G (p.Cys1554Gly) het [rs112089123, MAF *: 0.58%-0.31%-0.58%]		Spastic quadriplegiaP106
SQSTM13c.833C>Tp.Thr278Ile0%-0%-0%rs200445838 MyopathyP043
UBQLN23c.809G>A hemp.Arg270His0%-0%-0%rs767597171 Spinal ALS (Flail arm)P017
SETX3c.-114-2A>Gp.?0.08%-0%-0%rs560095915 Bulbar ALS, onset 43 yearsP079
SETX3c.934A>Gp.Ile312Val0%-0%-0% Spinal ALS, onset 67 yearsP045
SETX3c.2344G>Tp.Val782Leu0%-0%-0% (AR) ALS2: c.37G > A (p.Gly13Arg) het [rs367871772, MAF *: 0%-0.01%-0.01%] (Class 4);Lower motor neuron involvement, onset 21 yearsP071
SETX3c.3494C>Gp.Ser1165Cys0%-0%-0% Spinal ALS, onset 72 yearsP029
SETX3c.4220A>Gp.Asn1407Ser0%-0%-0%rs747050949 Bulbar ALS, onset 79 yearsP069
SETX3c.4957A>Gp.Lys1653Glu0%-0%-0% Spinal ALS, onset 66 yearsP088
ANG3c.61C>Tp.Pro21Ser0%-0.02%-0.02%rs149672657(HMN) TRPV4: c.1006C > T (p.Arg336Cys) het [rs781229110, MAF *: 0%-0%-0%] (Class 3);
(Class 2) SQSTM1: c.712A > G (p.Lys238Glu) het [rs11548633, MAF *: 0.24%-0.26%-0.24%]
(Class 2) SETX: c.3229G > A (p.Asp1077Asn) het [rs145097270, MAF *: 0.08%-0.07%-0.11%]		Spinal ALSP094
CHMP2B3c.36T>Gp.Asp12Glu0%-0%-0% (Class 2) GRN: c.264+7G > A (p = ?)het [rs60100877, MAF *: 0.5%-0.6%-0.53%]Spinal ALS, onset 71 yearsP074
ERBB43c.421 + 5G>Ap.? HSF: Alteration of the WT donor site, most probably affecting splicing0%-0%-0%rs778195807 -P024
NRBB43c.1441A>Gp.Ile481Val0%-0.01%-0%rs368860175 Bulbar ALS, onset 70. One affected siblingP092
MATR33c.1132G>Ap.Ala378Thr0%-0.03%-0.01%rs201075828 Spinal ALS, onset 37 yearsP099
GARS13c.302G>Ap.Arg101His0.02%-0.02%-0.04%rs200887429 -P005
GARS13c.302G>Ap.Arg101His0.02%-0.02%-0.04%rs200887429 Spinal ALSP030
GARS13c.571A>Tp.Thr191Ser0%-0%-0%rs760133861(Class 2) GARS1: c.803C > T (p.Thr268Ile) het [rs2230310, MAF *: 0.12%-0.48% 0.32%Spinal ALSP062
GARS13c.1159G>Ap.Ala387Thr0%-0%-0%rs776528885 Bulbar ALS and FTDP065
GRN3c.-8 + 7G>Cp?0%-0%-0% Bulbar ALSP054
GRN3c.329G>Ap.Arg110Gln0.02%-0.01%-0.01%rs375439809 NeuroacanthocytosisP110
GRN3c.1528C>Tp.Arg510Cys0%-0%-0%rs747873577 Spinal ALSP034
GRN3c.1691G>Ap.Arg564His0%-0%-0% Spinal ALSP035
MAPT3c.64G>Ap.Asp22Asn0%-0%-0%rs745662662(AR) IGHMBP2: c.2362C > T (p.Arg788Ter) het [rs199839840, MAF *: 0%-0.01%-0% (Class5)Spinal ALSP059
MAPT3c.319G>Ap.Gly107Ser0%-0%-0%rs769901930 Spinal ALS and mild cognitive impairmentP057
TRPV43c.113A>Gp.Asn38Ser0.02%-0%-0%rs527355587(Class 2) TRPV4: c.2518G > A (p.Glu840Lys) het [rs55728855, MAF *: 0.24%-0.74%-0.63%ALS monomelic typeP033
TRPV43c.1496C>Tp.Pro499Leu0.02%-0%-0%rs115358347 -P093
* MAF% (minor allele frequency) in 1000Genomes-Go-ESP–ExAC. Hem: hemizygous; het: heterozygous; HSF: Human Splicing Finder; (Suscep.): variants in susceptibility genes; (AR): variants in autosomal recessive genes; (HMN): variants in motor neuronopathy disease genes. het: heterozygous; (AR): variants in autosomal recessive genes.

Share and Cite

MDPI and ACS Style

Pensato, V.; Magri, S.; Dalla Bella, E.; Tannorella, P.; Bersano, E.; Sorarù, G.; Gatti, M.; Ticozzi, N.; Taroni, F.; Lauria, G.; et al. Sorting Rare ALS Genetic Variants by Targeted Re-Sequencing Panel in Italian Patients: OPTN, VCP, and SQSTM1 Variants Account for 3% of Rare Genetic Forms. J. Clin. Med. 2020, 9, 412. https://doi.org/10.3390/jcm9020412

AMA Style

Pensato V, Magri S, Dalla Bella E, Tannorella P, Bersano E, Sorarù G, Gatti M, Ticozzi N, Taroni F, Lauria G, et al. Sorting Rare ALS Genetic Variants by Targeted Re-Sequencing Panel in Italian Patients: OPTN, VCP, and SQSTM1 Variants Account for 3% of Rare Genetic Forms. Journal of Clinical Medicine. 2020; 9(2):412. https://doi.org/10.3390/jcm9020412

Chicago/Turabian Style

Pensato, Viviana, Stefania Magri, Eleonora Dalla Bella, Pierpaola Tannorella, Enrica Bersano, Gianni Sorarù, Marta Gatti, Nicola Ticozzi, Franco Taroni, Giuseppe Lauria, and et al. 2020. "Sorting Rare ALS Genetic Variants by Targeted Re-Sequencing Panel in Italian Patients: OPTN, VCP, and SQSTM1 Variants Account for 3% of Rare Genetic Forms" Journal of Clinical Medicine 9, no. 2: 412. https://doi.org/10.3390/jcm9020412

APA Style

Pensato, V., Magri, S., Dalla Bella, E., Tannorella, P., Bersano, E., Sorarù, G., Gatti, M., Ticozzi, N., Taroni, F., Lauria, G., Mariotti, C., & Gellera, C. (2020). Sorting Rare ALS Genetic Variants by Targeted Re-Sequencing Panel in Italian Patients: OPTN, VCP, and SQSTM1 Variants Account for 3% of Rare Genetic Forms. Journal of Clinical Medicine, 9(2), 412. https://doi.org/10.3390/jcm9020412

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop